Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea

被引:1
|
作者
Ikegami, T
Ha, L
Arimori, K
Latham, P
Kobayashi, K
Ceryak, S
Matsuzaki, Y
Bouscarel, B
机构
[1] George Washington Univ, Med Ctr, Dept Med, Washington, DC 20037 USA
[2] George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA
[3] George Washington Univ, Med Ctr, Dept Pathol, Washington, DC 20037 USA
[4] George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA
[5] Miyazaki Med Coll, Dept Pharm, Miyazaki 8891692, Japan
[6] Saitama Canc Ctr, Ina, Saitama 3360011, Japan
[7] Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3050024, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The therapeutic efficacy of irinotecan (CPT-11), a DNA topoisomerase inhibitor, is often limited by the induction of severe late-onset diarrhea. This prodrug and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), have a labile a-hydroxy-lactone ring that undergoes pH-dependent reversible hydrolysis. At physiological pH and higher, equilibrium favors the less toxic carboxylate form, whereas at acidic pH, the more potent lactone form is favored. We have reported previously that the initial uptake rate of CPT-11 and SN-38 by intestinal cells was significantly different between the respective lactone and carboxylate form. Results from the present study in HT-29 cells further demonstrate the correlation between the CPT-11/SN-38 initial uptake rate and the induced toxicity, cell cycle alteration, apoptosis, and colony-forming efficiency. The exposure of HT-29 cells to SN-38 for a limited period of time (<2 h) was sufficient to induce these events. Because the decreased initial uptake of SN-38 carboxylate resulted in a reduced cellular toxicity, we postulated that the CPT-11-induced diarrhea was preventable by influencing the equilibrium toward the carboxylate form and, thus, reducing its intestinal uptake. In the golden Syrian hamster model, p.o. sodium bicarbonate supplementation (5 mg/ml in drinking water) led to alkalization of the intestinal contents. In addition, this alkalization resulted in the reduction of the histopathological damage to the mucosa of the small and large intestine, as well as a 20% reduction of the intestinal SN-38 lactone concentration of animals receiving CPT-11 (20-50 mg/kg X 7 days). Taken together, these results from in vitro and in vivo studies support intestinal alkatization by sodium bicarbonate supplementation as a preventive mechanism against CPT-11-induced diarrhea. In addition, this provides a strong rationale for the usage of this measure as an adjunct to CPT-11 treatment.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 50 条
  • [1] Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients
    Takeda, Y
    Kobayashi, K
    Akiyama, Y
    Soma, T
    Handa, S
    Kudoh, S
    Kudo, K
    INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (02) : 269 - 275
  • [2] Effect of intestinal alkalinization on Irinotecan (CPT-11)-induced diarrhea in the golden Syrian hamster model
    Ikegami, T
    Latham, P
    Kobayashi, K
    Arimori, K
    Bouscarel, B
    GASTROENTEROLOGY, 2001, 120 (05) : A613 - A613
  • [3] The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)
    Dodds, HM
    Rivory, LP
    MOLECULAR PHARMACOLOGY, 1999, 56 (06) : 1346 - 1353
  • [4] THE ROLE OF INTESTINAL AND HEPATIC GLUCURONIDATION IN CHEMOTHERAPY INDUCED TOXICITY BY IRINOTECAN (CPT-11)
    Chen, Shujuan
    Yueh, Mei-Fei
    Barbier, Olivier
    Bigo, Cyril
    Wang, Kepeng
    Karin, Michael
    Nguyen, Nghia
    Tukey, Robert H.
    DRUG METABOLISM REVIEWS, 2014, 45 : 20 - 21
  • [5] Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea
    K. Takasuna
    T. Hagiwara
    K. Watanabe
    S. Onose
    S. Yoshida
    E. Kumazawa
    E. Nagai
    T. Kamataki
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 494 - 503
  • [6] Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11)
    Chen, Shujuan
    Yueh, Mei-Fei
    Bigo, Cyril
    Barbier, Olivier
    Wang, Kepeng
    Karin, Michael
    Nghia Nguyen
    Tukey, Robert H.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (47) : 19143 - 19148
  • [7] Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea
    Takasuna, K.
    Hagiwara, T.
    Watanabe, K.
    Onose, S.
    Yoshida, S.
    Kumazawa, E.
    Nagai, E.
    Kamataki, T.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 494 - 503
  • [8] Pathophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhea (DD): A prospective assessment
    Misset, JL
    Saliba, F
    Giacchetti, S
    Brain, E
    Vassal, G
    Bonnay, M
    Bastian, G
    Cote, C
    Mahjoubi, M
    Herait, P
    Hagipantelli, R
    Cvitkovic, E
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 742 - 742
  • [9] Irinotecan (CPT-11) for multiple myeloma
    Yano, H.
    Iida, S.
    Kayukawa, S.
    Nakagawa, C.
    Oguri, T.
    Ri, M.
    Inagaki, A.
    Sanda, T.
    Kusumoto, S.
    Ishida, T.
    Komatsu, H.
    Suzuki, A.
    Ueda, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 140 - 140
  • [10] Clinical pharmacogenetics of irinotecan (CPT-11)
    Ando, Y
    Hasegawa, Y
    DRUG METABOLISM REVIEWS, 2005, 37 (03) : 565 - 574